Payment overview · 2025
General Payments
$1,413.32
50 reported records · 20 companies
Healthcare provider profile · identity verified
Juan Silva, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1790738110
Verified facts
What the public records show
CMS Open Payments records show Juan Silva, MD received $1,413.32 in general payments during 2025 across 50 reported records.
Abbott Laboratories accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $250.33 | 17.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $213.15 | 15.1% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $156.37 | 11.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.12 | 8.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.21 | 8.2% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $96.46 | 6.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.67 | 6.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.56 | 4.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.35 | 3.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.03 | 3.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.66 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.55 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.17 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.70 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.92 | 1.6% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $19.60 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.67 | 1.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $12.99 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,413.32 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $250.33 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $156.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.72 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.21 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $88.67 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.41 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.02 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $71.33 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.56 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $57.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.10 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $12.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 296 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 272 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
56 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
296 | 84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
296 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
272 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 746 | 252 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 109 |
| Losartan Potassium | Losartan Potassium | 394 | 132 |
| Metformin Hcl | Metformin Hcl | 359 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 112 |
| Jardiance | Empagliflozin | 296 | 84 |
| Ozempic | Semaglutide | 272 | 47 |
| Omeprazole | Omeprazole | 255 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 82 |
| Lisinopril | Lisinopril | 231 | 75 |
| Gabapentin | Gabapentin | 202 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 69 |
| Ezetimibe | Ezetimibe | 181 | 74 |
| Famotidine | Famotidine | 170 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 68 |
| Azithromycin | Azithromycin | 133 | 92 |
| Carvedilol | Carvedilol | 127 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 36 |
| Tramadol Hcl | Tramadol Hcl | 115 | 27 |
| Benazepril Hcl | Benazepril Hcl | 111 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 42 |
| Liothyronine Sodium | Liothyronine Sodium | 106 | 33 |
| Furosemide | Furosemide | 103 | 39 |
| Celecoxib | Celecoxib | 102 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 38 |
| Mirtazapine | Mirtazapine | 101 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 99 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 36 |
| Prednisone | Prednisone | 97 | 60 |
| Ibuprofen | Ibuprofen | 94 | 36 |
| Lorazepam | Lorazepam | 94 | 30 |
| Chlorthalidone | Chlorthalidone | 91 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 29 |
| Alendronate Sodium | Alendronate Sodium | 90 | 29 |
| Temazepam | Temazepam | 87 | 14 |
| Alprazolam | Alprazolam | 83 | 13 |
| Baclofen | Baclofen | 82 | 31 |
| Levofloxacin | Levofloxacin | 82 | 63 |
| Farxiga | Dapagliflozin Propanediol | 80 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 51 |
| Eliquis | Apixaban | 73 | 27 |
| Ketoconazole | Ketoconazole | 70 | 30 |
| Simvastatin | Simvastatin | 70 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 13 |
| Clonazepam | Clonazepam | 66 | 14 |
| Azelastine Hcl | Azelastine Hcl | 63 | 28 |
| Trazodone Hcl | Trazodone Hcl | 60 | 20 |
| Finasteride | Finasteride | 59 | 26 |
| Glipizide | Glipizide | 58 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 18 |
| Creon | Lipase/Protease/Amylase | 56 | 18 |
| Meclizine Hcl | Meclizine Hcl | 56 | 23 |
| Donepezil Hcl | Donepezil Hcl | 55 | 17 |
| Ondansetron Odt | Ondansetron | 55 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 19 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 23 |
| Allopurinol | Allopurinol | 47 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 17 |
| Januvia | Sitagliptin Phosphate | 46 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Lidocaine | Lidocaine | 45 | 15 |
| Naproxen | Naproxen | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 42 | 14 |
| Loperamide | Loperamide Hcl | 42 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Clotrimazole | Clotrimazole | 40 | 21 |
| Lactulose | Lactulose | 40 | 17 |
| Methocarbamol | Methocarbamol | 40 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Fluconazole | Fluconazole | 39 | 28 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 17 |
| Meloxicam | Meloxicam | 37 | 13 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | 16 |
| Nifedipine Er | Nifedipine | 35 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Amoxicillin | Amoxicillin | 34 | 16 |
| Rybelsus | Semaglutide | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 13 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 11 |
| Vascepa | Icosapent Ethyl | 29 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Linzess | Linaclotide | 28 | 11 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Atenolol | Atenolol | 27 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 13 |
| Dexamethasone | Dexamethasone | 26 | 15 |
| Glipizide Er | Glipizide | 26 | 12 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 18 |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | 13 |
| Nystatin | Nystatin | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Quviviq | Daridorexant Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,413.32 · 50 records | Abbott Laboratories | ABRYSVO, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, CeQur Simplicity, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, Grastek, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, Odactra, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, ROTATEQ, Ragwitek, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VAQTA, VAXNEUVANCE, VERQUVO, VOQUEZNA, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error